The first connection of CK2 to cancer dates back to 1995 when Seldin and Leder discovered that a lymphoproliferative syndrome was associated with CK2 overexpression, and that the co-expression of CK2 catalytic subunit and c-myc was capable of transforming lymphocytes.39 Since then, CK2 was found overexpressed in several cancer cells in comparison to healthy counterparts, and a plethora of studies was published supporting functions of CK2 in the pathogenesis of cancer. The gene discussed is MYC; the disease is cancer.